Though the tumor promoter and cellular antioxidant Trx-1, which is inhibited by TXNIP, has been shown to confer more aggressive disease in other cancers [30-34], our data failed to show differences in Trx-1 expression levels between DTC and ATC cells. This evidence concerns the gene TXN and cancer.